Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia

Keyphrases

• Phase 1 Study 100%
• Acute Myeloid Leukemia 100%
• Complete Remission 100%
• MDM2 Antagonist 100%
• Idasanutlin 100%
• Dose-limiting Toxicity 50%
• Maximum Tolerated Dose 50%
• Pharmacokinetics 50%
• Leukemia 50%
• Tumor Protein p53 (TP53) 50%
• Free State 50%
• Antileukemic Activity 50%
• Hematologic Recovery 50%
• Response Rate 25%
• Adverse Events 25%
• Monotherapy 25%
• Diarrhea 25%
• TP53 mutation 25%
• Dysregulation 25%
• Pharmacodynamic Interactions 25%
• Safety Profile 25%
• Partial Response 25%
• Stable Disease 25%
• Near-complete 25%
• Nausea-vomiting 25%
• Pharmacodynamics 25%
• Prodrug 25%
• Disease Control Rate 25%
• Pharmacokinetics-pharmacodynamics (PK-PD) 25%
• Pharmacokinetic Effects 25%
• IV Administration 25%
• Platelet Recovery 25%
• Decreased Appetite 25%
• Wild-type p53 25%
• P53 Activation 25%
• PEGylated Prodrug 25%
• Complete Conversion 25%
• Hematologic Improvement 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Remission 100%
• Acute Myeloid Leukemia 100%
• Idasanutlin 100%
• Pharmacokinetics 75%
• Maximum Tolerated Dose 50%
• Pharmacodynamics 50%
• Leukemia 50%
• Prodrug 50%
• Protein P53 50%
• Diseases 50%
• Monotherapy 25%
• Diarrhea 25%
• Nausea 25%
• Adverse Event 25%
• Biological Product 25%
• Decreased Appetite 25%

Medicine and Dentistry

• Acute Myeloid Leukemia 100%
• Idasanutlin 100%
• Pharmacokinetics 75%
• Morphology 50%
• Protein P53 50%
• Pharmacodynamics 50%
• Leukemia 50%
• Prodrug 50%
• Diseases 50%
• Oral 50%
• Nausea 25%
• Adverse Event 25%
• Monotherapy 25%
• Diarrhea 25%
• Platelet 25%
• Biological Product 25%
• Decreased Appetite 25%